Physician Perspectives 2017: Biosimilar use in IBD
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
› Questions topics:
– Familiarity with biosimilar IFX
– Expected use of biosimilars – IFX & ADA
– Concerns with biosimilars
– Switching & Interchangeability
Scope
› Sociable Pharma conducted an online survey in Q4 2017, with 100 specialist gastroenterologists
› Physicians interviewed were from 5EU and US countries › This report contains the findings from the survey, together with analysis, as well as an overview of the methodology used, and responder demographics
Key Highlights
In the next 12 months, nearly half of physicians stated that they would consider switching Remicade patients (in remission) over to biosimilar IFX
A large proportion of physicians reported that their patients have at least occasionally expressed concern (rated >3) over being switched onto a biosimilar anti-TNF from an originator anti-TNF (67%) or being prescribed a biosimilar anti-TNF (54%)
Overall, the majority of physicians agreed that they would require a biosimilar to be designated as interchangeable before considering switching patients from an originator to a biosimilar (67%)
Reasons to Buy
Qualitative insight from 100 high-prescribing specialists in IBD
Includes insight & recommendations from our disease-specific healthcare analysts
Utilizes independent expert viewpoints to validate the impact of emerging trends on management of IBD
Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion
Celltrion
AbbVie
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.